Business Wire

Mary Kay Challenges Global Youth to Address SDG 14: Life Below Water in Third Annual Network for Teaching Entrepreneurship World Series of Innovation Challenge

15.9.2022 18:05:00 EEST | Business Wire | Press release

Share

Mary Kay Inc., a leading corporate advocate of women’s empowerment and entrepreneurship, announces its third annual World Series of Innovation (WSI) challenge in partnership with Network for Teaching Entrepreneurship (NFTE). The global competition invites young people ages 13-24 to put their critical thinking skills to the test and get involved in solving some of the biggest challenges humanity faces today to advance the UN Sustainable Development Goals (SDGs).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005847/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Network for Teaching Entrepreneurship an international nonprofit organization providing entrepreneurship training and educational programs to middle and high school students, college students, and adults (Graphic: Network for Teaching Entrepreneurship)

Mary Kay’s WSI challenge kicks off September 15 in conjunction with World Clean Up Day. The Mary Kay challenge encourages young entrepreneurs to submit innovative solutions to address UN SDG 14: Life Below Water. Specifically, students are challenged to design a solution to further the conservation and/or protection of the world’s marine ecosystems and coastal communities.

“All life on Earth began in and depends on our oceans. Water is the most valuable resource on our planet, and it’s essential that we not only respect it, but do our part to protect it,” said Deborah Gibbins, Chief Operating Officer for Mary Kay Inc. “The next generation of global thinkers and leaders are already addressing these critical areas of concern and spearheading conservation efforts. We are excited to see how the world’s youth can help to advance ecosystems and biodiversity conservation globally.”

In its first year partnering with the NFTE World Series of Innovation in 2020, Mary Kay sponsored a WSI challenge for UN SDG 12: Responsible Consumption and Production. Young entrepreneurs were encouraged to design a product, service or initiative that promoted the reuse or upcycling of textiles. In 2021, Mary Kay sponsored its second WSI challenge to address UN SDG 5: Gender Equality. Students were tasked with developing programs to promote workplace equality and ensure equal access to economic opportunity for women and girls.

“Mary Kay Global Oceans Conservations Challenge dares our young WSI competitors to think big about water quality,” said Dr. J.D. LaRock, President and CEO of NFTE. “In classrooms, students learn that water is fundamental to a healthy ecosystem. Through experiences like WSI, however, they become empowered to sustain that resource. They can ideate ways to look after marine life, safeguard oceans, secure affordable access to clean drinking water, protect water resources from pollution, address overconsumption, or otherwise help preserve our ecosystem for generations to come. That’s powerful.”

NFTE is a global educational non-profit focused on bringing the power of entrepreneurship to low-income communities. Since its founding more than 35 years ago, NFTE has trained thousands of teachers and educated well over a million young people worldwide. Every fall, NFTE launches a new set of challenges for the WSI competition and invites corporate sponsors to address the UN SDGs. The 2022 NFTE World Series of Innovation is presented by Citi Foundation and features challenges sponsored by Mary Kay Inc., MetLife Foundation, Mastercard, Bank of the West, Link, Maxar, Ernst & Young, LLP (EY), ServiceNow and Zuora. The top three winners will be announced in early 2023.

For more information on the World Series of Innovation and all challenges, visit https://innovation.nfte.com/.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release

The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release

Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye